Dosage Study for Vigamox Eye Drops Prior to Intravitreal Injections
Information source: Illinois Retina Associates
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Intravitreal Injection Patients
Intervention: Vigamox (Drug)
Phase: Phase 4
Status: Not yet recruiting
Sponsored by: Illinois Retina Associates Official(s) and/or principal investigator(s): Kourous A Rezaei, MD, Principal Investigator, Affiliation: Illinois Retina Associates SC
Overall contact: Kourous A Rezaei, MD, Phone: 708-596-8710, Email: karezaei@yahoo.com
Summary
Antibiotic eye drops are being used before and after intravitreal injections. Currently
there is no study indicating the benefit of there usage or their dosage.
In this study we compare the efficacy of Vigamox eye drops (antibiotic)starting 3 days prior
to the injection versus 1 day prior to intravitreal injection.
Clinical Details
Official title: To Compare the Efficacy of Topical Vigamox Eye Drops at Tid 3 Days Prior to Intravitreal Injection Versus Tid 1 Day Prior to Intravitreal Injection
Study design: Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Timed study
Eligibility
Minimum age: 21 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Patient who need intravitreal injections patients who are willing to participate in
the study
Exclusion Criteria:
- Patients who are allergic to Vigamox or who have taken any eye drops within the past
3 weeks
Locations and Contacts
Kourous A Rezaei, MD, Phone: 708-596-8710, Email: karezaei@yahoo.com
Illinois Retina Associates, Harvey, Illinois 60426, United States; Not yet recruiting David J Baczewski, Phone: 708-915-6808, Email: davidb@illinoisretina.com Kourous A Rezaei, MD, Principal Investigator
Additional Information
Starting date: July 2008
Last updated: June 3, 2008
|